A
Exchange
—
Entity type
operating
Fiscal year end
Dec 31
Headquarters
DE
Recent Filings
- SC 13G/A109.5 KBALPINE IMMUNE SCIENCES, INC.Nov 14, 4:45 PM ET·0001172661-24-005283
- SC 13D/A81.4 KBALPINE IMMUNE SCIENCES, INC.May 21, 4:49 PM ET·0001104659-24-063883
- SC 13D/A177.2 KBALPINE IMMUNE SCIENCES, INC.May 21, 10:21 AM ET·0001193125-24-143527
- 8-K361.4 KBALPINE IMMUNE SCIENCES, INC.May 20, 8:38 AM ET·0001193125-24-142285
- 10-Q5.2 MBALPINE IMMUNE SCIENCES, INC.May 9, 4:22 PM ET·0001626199-24-000064
- 8-K247.3 KBALPINE IMMUNE SCIENCES, INC.May 9, 4:09 PM ET·0001626199-24-000063
- SC 13D/A111.0 KBALPINE IMMUNE SCIENCES, INC.Apr 30, 4:20 PM ET·0001104659-24-054965
- SC 13D/A244.0 KBALPINE IMMUNE SCIENCES, INC.Apr 29, 6:08 PM ET·0001193125-24-123019
- 10-K/A816.9 KBALPINE IMMUNE SCIENCES, INC.Apr 25, 7:48 PM ET·0001626199-24-000059
- 8-K931.6 KBALPINE IMMUNE SCIENCES, INC.Apr 10, 4:26 PM ET·0001193125-24-091936
Insiders
10- CONWAY ROBERT EDirector
- Cui XiangminDirector, 10% Owner
- Decheng Capital China Life Sciences USD Fund III, L.P.10% Owner
- Decheng Capital Management III (Cayman), LLC10% Owner
- Drappa JornDirector
- Dummer WolfgangChief Medical Officer
- DURAND REMYChief Business Officer
- FUHS ULRICH MARTINChief Accounting Officer
- Furst Howard P.Director
- GOLD MITCHELLDirector, Executive Chairman and CEO
Tickers
No tickers on record
Addresses
business
188 EAST BLAINE ST., SUITE 200
SEATTLE, WA, 98102
mailing
188 EAST BLAINE ST., SUITE 200
SEATTLE, WA, 98102
Former Names
- Nivalis Therapeutics, Inc.2017-07-25
- N30 Pharmaceuticals, Inc.2014-11-25